Recent human studies indicate that increased circulating levels of FGF-21 are found in obese individuals and subjects with metabolic syndrome or type 2 diabetes [18], [19] and are closely associated with obesity [18], [20] and renal dysfunction in chronic hemodialysis [21]. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.